Q4 FY2025 · ended Dec 31, 2025 · Revenue $0, -100.0% YoY · Filed Mar 26, 2026
Zentalis Pharmaceuticals, Inc. (ZNTL) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$37.2 million. As of Jun 30, 2026 it held $174.6 million in cash and investments and $37.7 million in total debt.
Revenue
$0
-100.0% vs year-ago quarter
Net income
$-42.29M
-57.3% vs year-ago quarter
Operating cash flow
$-37.24M
-7.3% vs year-ago quarter
Free cash flow
$-37.24M
-7.3% vs year-ago quarter
EPS
$-0.59
-59.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
71.67M
-0.6% vs year-ago quarter
Net cash
$136.92M
Q2 FY2026
Operating margin
-185.6%
Q4 FY2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ZNTL (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1725160
- Former names
- Zentalis Pharmaceuticals, LLC (until Apr 6, 2020); Zeno Pharma, LLC (until Sep 5, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 |
| Operating income | -$44.4M | -$37.9M | -$37.4M | -$33.7M | -$36.1M |
| Net income | -$42.3M | -$35.4M | -$35.2M | -$26.7M | -$26.9M |
| Diluted EPS | -$0.59 | -$0.50 | -$0.49 | -$0.37 | -$0.37 |
| Operating cash flow | -$37.2M | -$33.0M | -$30.9M | -$27.0M | -$34.7M |
| Free cash flow | -$37.2M | -$33.0M | -$30.9M | -$27.0M | -$34.7M |
| Total assets | $215.3M | $253.1M | $289.0M | $327.2M | $351.7M |
| Total liabilities | $71.7M | $70.4M | $72.8M | $74.4M | $77.2M |
| Stockholders' equity | $143.6M | $182.7M | $216.2M | $252.9M | $274.5M |
| Cash and investments | $174.6M | $211.8M | $245.9M | $278.3M | $286.6M |
| Total debt | $37.7M | $38.7M | $39.6M | $40.5M | $41.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Aug 14, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 16, 2026 |
| 8-K |
Current report
Officer or director change
|
May 27, 2026 | May 22, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 21, 2026 | May 21, 2026 |
All 546 Zentalis Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.